



# ESMO Preceptorship on Ovarian Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**LISBON PORTUGAL  
25-26 SEPTEMBER 2024**

**Co-Chairs**

Jonathan A. Ledermann, United Kingdom  
Sven Mahner, Germany

# ESMO PRECEPTORSHIP PROGRAMME

## OVARIAN CANCER

Multidisciplinary management, standards of care  
and future perspectives

Lisbon, Portugal  
25-26 September 2024

---

### CO-CHAIRS

Jonathan A. Ledermann, United Kingdom  
Sven Mahner, Germany

### SPEAKERS

Elena Ioana Braicu, Germany  
Nicoletta Colombo, Italy  
Mojgan Devouassoux-Shisheboran, France  
Antonio González Martín, Spain  
Philipp Harter, Germany  
Florence Joly, France  
Ainhoa Madariaga, Spain  
Frederik Marmé, Germany  
Shibani Nicum, United Kingdom

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side effects of treatment

---

## ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, CH  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 25 September 2024

<b>09:00-09:10</b> 10'	<b>Welcome and introduction</b>	<b>Jonathan A. Ledermann, UK</b> <b>Sven Mahner, DE</b>
<b>09:10-10:25</b> 75'	<b>SESSION 1</b> <b>Early stage disease</b>	<b>Chairs:</b> <b>Nicoletta Colombo, IT</b> <b>Ainhoa Madariaga, ES</b>
20'	Overview on pathology and classification of epithelial carcinoma, including molecular profile	Mojgan Devouassoux-Shisheboran, FR
20'	Surgical management and FIGO staging of early ovarian cancer (including fertility preservation)	Sven Mahner, DE
20'	Medical management of early ovarian cancer	Frederik Marmé, DE
15'	Q&A	All
<b>10:25-10:55</b>	<b>Coffee break</b>	
<b>10:55-12:30</b> 95'	<b>SESSION 2</b> <b>Biology of ovarian cancer and rare tumours</b>	<b>Chairs:</b> <b>Antonio González Martín, ES</b> <b>Philipp Harter, DE</b>
20'	Pathology and molecular profile of non-epithelial and rare ovarian tumours	Mojgan Devouassoux-Shisheboran, FR
15'	Germ cell tumours	Florence Joly, FR
15'	Sex cord stromal tumours	Nicoletta Colombo, IT
15'	Low-grade tumours	Shibani Nicum, UK
15'	Clear cell and mucinous tumours	Ainhoa Madariaga, ES
15'	Q&A	All
<b>12:30-13:30</b>	<b>Lunch</b>	
<b>13:30-15:35</b> 125'	<b>SESSION 3</b> <b>Advanced stage disease</b>	<b>Chairs:</b> <b>Florence Joly, FR</b> <b>Shibani Nicum, UK</b>
30'	Surgical pathways for newly diagnosed advanced ovarian cancer	Sven Mahner, DE
20'	Biology and biomarkers in clinical practice (including ctDNA)	Elena Ioana Braicu, DE
30'	First-line and maintenance chemotherapy	Jonathan A. Ledermann, UK
30'	Participants clinical case discussion (3x10')	Faculty
15'	Q&A	All
<b>15:35-16:05</b>	<b>Coffee break</b>	
<b>16:05-18:00</b> 115'	<b>SESSION 4</b> <b>Recurrent disease</b>	<b>Chairs:</b> <b>Jonathan A. Ledermann, UK</b> <b>Sven Mahner, DE</b>
20'	The role of surgery in recurrent ovarian cancer	Philipp Harter, DE

20'	Challenges of systemic treatment – Platinum and non-platinum chemotherapies, treatment in the post-PARPi era	Antonio González Martín, ES
15'	Emerging strategies: Antibody-drug conjugates	Ainhoa Madariaga, ES
15'	Emerging strategies: Immunotherapy	Antonio González Martín, ES
30'	Participants clinical case discussion (3x10')	Faculty
15'	Q&A	All
<b>20:00</b>	<b>Dinner</b>	

## Thursday, 26 September 2024

<b>09:00-09:30</b> 30'	<b>SESSION 5</b> <b>Keynote sunrise lecture</b>	<b>Chair:</b> <b>Sven Mahner, DE</b>
25'	History and reflections on the treatment of ovarian cancer	Jonathan A. Ledermann, UK
5'	Q&A	All
<b>09:30-11:50</b> 110'	<b>SESSION 6</b> <b>Complex and special situations</b>	<b>Chairs:</b> <b>Elena Ioana Braicu, DE</b> <b>Sven Mahner, DE</b>
20'	Frailty assessment and patient related outcomes	Florence Joly, FR
15'	Cancer during pregnancy and pregnancy after cancer	Nicoletta Colombo, IT
15'	Management of menopausal symptoms after cancer treatment	Shibani Nicum, UK
<b>10:20-10:50</b>	<b>Coffee break</b>	
15'	Role of HIPEC in ovarian cancer	Philipp Harter, DE
30'	Participants clinical case discussion (3x10')	Faculty
15'	Q&A	All
<b>11:50-12:55</b> 65'	<b>SESSION 7</b> <b>Future strategies</b>	<b>Chairs:</b> <b>Mojgan Devouassoux-Shisheboran, FR</b> <b>Jonathan A. Ledermann, UK</b>
25'	Drug resistance and how to overcome PARP inhibitors resistance	Elena Ioana Braicu, DE
25'	Novel treatment pathways and combinations: Horizon scanning	Frederik Marmé, DE
15'	Q&A	All
<b>12:55-13:10</b> 15'	<b>Conclusion and farewell</b>	<b>Jonathan A. Ledermann, UK</b> <b>Sven Mahner, DE</b>
<b>13:10-14:10</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion